New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
OverviewChart

Quote Panel

Shape
Updated April 27, 2025
1W -4.28 % 1M -18.17 % 3M -54.97 % 1Y -62.99 %

Key Metrics

Shape

  • Market Cap

    44.14M

  • Shares Outstanding

    6.58M

  • Share in Float

    5.32M

  • Dividende

    0

  • Earning Date

    12 May 2025

  • Price Target

    6.7068

  • Average Volume

    34520

  • Beta

    2.857

  • Range

    4.11-28.68

  • Industry

    Biotechnology

  • Website

    https://www.fortebiorx.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

0.00x

P/S Ratio

0.30x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-12.2

EPS

How FBRX compares to sector?

P/E Ratio

FBRX

0x

INDP 0x
RZLT -4x
TPST -5x
CMRA 0x
ABVC -2x

Relative Strength

Shape

FBRX

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape
0

$3.60

Shape-20%

2025-EPS

0

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Shape

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Rodman & Renshaw

initialise

Previous: Not converted

2024-06-18

Now: Buy

Brookline Capital

initialise

Previous: Not converted

2024-05-29

Now: Buy

Earnings GrowthShape

status-upYoY

Current

Estimates

Q1.23

arrow
arrow

N/A

-8.00
vs -4.25

Q2.23

arrow
arrow

N/A

-10.50
vs -5.25

Q3.23

arrow
arrow

N/A

-6.50
vs -4.50

Q4.23

arrow
arrow

N/A

-1.00
vs -6.00

Q1.24

arrow
arrow

N/A

-4.00
vs -8.00

Q2.24

arrow
arrow

N/A

-6.75
vs -10.50

Q3.24

arrow
arrow

N/A

-4.54
vs -6.50

Q4.24

arrow
arrow

N/A

-2.45
vs -1.00

Q1.25

arrow
arrow

N/A

-0.95
vs -4.00

Q2.25

arrow
arrow

N/A

-1.11
vs -6.75

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

NA

NA  vs NA

Q4.22

arrow
arrow

NA

NA  vs NA

Q1.23

arrow
arrow

NA

NA  vs NA

Q2.23

arrow
arrow

NA

NA  vs NA

Q3.23

arrow
arrow

NA

NA  vs NA

Q4.23

arrow
arrow

NA

6K  vs NA

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Q3.24

arrow
arrow

NA

NA  vs NA

Q4.24

arrow
arrow

-100%

NA  vs 6K

Return on EquityShape

status-upQoQ

Q1.23

arrow
arrow

-20%

-0.20
vs -0.13

Q2.23

arrow
arrow

-36%

-0.36
vs -0.20

Q3.23

arrow
arrow

-25%

-0.25
vs -0.36

Q4.23

arrow
arrow

-17%

-0.17
vs -0.25

Q1.24

arrow
arrow

-26%

-0.26
vs -0.17

Q2.24

arrow
arrow

-74%

-0.74
vs -0.26

Q3.24

arrow
arrow

-90%

-0.90
vs -0.74

Q4.24

arrow
arrow

-14%

-0.14
vs -0.90

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

26

26
vs 32

-19%

Q4.22

arrow
arrow

33

33
vs 26

27%

Q1.23

arrow
arrow

30

30
vs 33

-9%

Q2.23

arrow
arrow

31

31
vs 30

3%

Q3.23

arrow
arrow

32

32
vs 31

3%

Q4.23

arrow
arrow

36

36
vs 32

13%

Q1.24

arrow
arrow

33

33
vs 36

-8%

Q2.24

arrow
arrow

34

34
vs 33

3%

Earnings Growth

Latest News

FBRX

zacks.com

9 hours ago

Here's Why Momentum in Forte Biosciences (FBRX) Should Keep going
FBRX

businesswire.com

9 hours ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
FBRX

zacks.com

10 hours ago

Forte Biosciences (FBRX) Is a Great Choice for 'Trend' Investors, Here's Why
FBRX

zacks.com

13 hours ago

All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy
FBRX

zacks.com

13 hours ago

Forte Biosciences (FBRX) Upgraded to Buy: What Does It Mean for the Stock?
FBRX

businesswire.com

16 hours ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules